Navigation Links
Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
Date:10/24/2011

SYDNEY, Oct. 24, 2011 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care."

Pharmaxis expects the European Commission to confirm this opinion and grant the Marketing Authorisation for Bronchitol in January 2012.

Pharmaxis CEO Dr Alan Robertson welcomed the decision saying, "This outcome from the CHMP meeting is an important milestone for the company.  It is good news for the cystic fibrosis (CF) community which has supported us throughout the development of Bronchitol.  As the life expectancy of CF patients has lengthened, the size of the adult population in Europe has increased.  Bronchitol will be used for CF patients aged 18 and above, which represents about two thirds of all patients who could potentially benefit from the drug. Pharmaxis will undertake a short term clinical trial in children (age 6-17) with a view to extending the license to this age group.

"Bronchitol is a drug which was discovered and developed in Australia.  It is approved for marketing in Australia and is now set to become available throughout the 27 countries of the European Union.  This outcome represents the culmination of a great deal of work by many people.

"Pharmaxis will move quickly to commercialise Bronchitol in Europe.  We have established our supply and logistics arrangements and advanced launch preparations and pricing applications with our marketing partner, Quintiles.  The awareness of Bronchitol's clinical data amongst CF clinicians has increased through publications and presentations at scientific conferences.  European clinicians provided valuable support to the CHMP decision and
'/>"/>

SOURCE Pharmaxis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
2. Pharmaxis Previews New Bronchial Challenge Test at the Annual Meeting of the American College of Allergy, Asthma and Immunology
3. Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
4. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
5. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
6. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
7. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
8. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
9. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
10. Pharmaxis Establishes Named Patient Program for Bronchitol
11. Pharmaxis Long-Term Safety Study of Bronchitol Completes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ViewRay™, a privately held medical device company, announced ... agreement with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) ... treatment of cancer in Japan . ... first and only MRI-guided radiation therapy system that images ...
(Date:1/22/2015)... (NASDAQ: AMGN ) today announced that it will report ... Jan. 27, 2015, after the close of the U.S. financial markets. ... investment community at 2 p.m. PT. Participating in the call from ... executive officer, and other members of Amgen,s senior management team. ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... addition of the "Microbiology Testing/Clinical Microbiology Market ... Global Forecast to 2019" report to their ... wide array of techniques for the detection of ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 2Global Microbiology Testing/Clinical Microbiology (Instrument, Analyzer, Incubator, Kit, Microscope, Molecular Diagnostics) Market - Forecast to 2019 3
... , FRANKLIN, Mass. , May 24 Arthrosurface, ... announced the achievement of a significant clinical milestone.  Over 20,000 patients, ... resurfacing systems, with the early patients now 6 years post surgery. ... "Back in ...
... At a town hall meeting a year ago, President Obama said that home-based ... people out of more expensive institutional care.  "I actually think homecare ends up ... people in their homes," the president told his audience in the Cleveland ... , , ...
Cached Medicine Technology:Arthrosurface® Hits the 20,000 Implant Milestone 2Medicare Policies Ignore Aging-at-Home Concept 2Medicare Policies Ignore Aging-at-Home Concept 3Medicare Policies Ignore Aging-at-Home Concept 4Medicare Policies Ignore Aging-at-Home Concept 5
(Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
(Date:1/22/2015)... Oceanside,CA (PRWEB) January 22, 2015 For over 20 ... the Oceanside and Vista area has treated just about ... other personal injury circumstances. And for those same twenty-plus years, ... victims of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... As interest in the value of spiritual support ... Rev. Eric J. Hall , president and CEO of ... be the keynote speaker on January 27 at an international ... , The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual ...
(Date:1/22/2015)... 22, 2015 State Forestry Institute of ... system with support from GEOSYSTEMS, a dedicated Hexagon Geospatial ... will leverage Hexagon Geospatial’s ERDAS APOLLO for ... well as point clouds and documents. This effort will ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 2Health News:State Forestry Institute Mecklenburg-Vorpommern, Germany Embraces Hexagon Geospatial Technology 3
... lost and becomes brittle, is one of the dreaded complications ... a result of decreased levels of estrogen, which is responsible ... of the University of Texas Medical Branch at Galveston, has ... may prevent bone loss after menopause as effectively as estrogen. ...
... women is on the rise. But the alarm bells are ... smokers with breast cancer face an increased risk of their ... nonsmokers ,"There is a relationship between smoking and ... MD, associate professor of medicine at the University of California ...
... libido, low motivation and fatigue, most often occurring in ... had been removed surgically for some reason. ,Dehydroepiandosterone(DHEA), ... dysfunction, according to a study released at the 96th ... California. This report was the end result of the ...
... Center reported in the current New England Journal of Medicine ... genes into six men suffering from hemophilia. This method ... producing the blood clotting protein they lack. None of ... the treatment. ,The study was designed only to test ...
... latest mantra of Pfizer. The pharmaceutical giant has announced ... hardest hit by the AIDS virus. The decision by the ... Government winning a landmark case against pharmaceutical companies. In ... Diflucan will be given free of cost to battle HIV ...
... Dr. Balakrishna Ganapat Rao Matapurkar, from Maulana Azad Medical ... winning the first patent on organ regeneration from the ... / repairing organs in human beings. ,A few ... patent on this technique. Dr. Matapurkar was able ...
Cached Medicine News:
... FoamWrap BuddyWraps hold the fingers safely together ... to use tape or prickly hook and ... washable, and offers unparalleled comfort. Available in ... The favorite choice of doctors and therapists. ...
... stability and control motion for persons with ... control due to stroke or cerebral palsy. ... plastic with broad bands to comfortably distribute ... the most versatile ring splint available. Whether ...
... of minor knee pain like arthritis, tendonitis ... with the motion of the knee, applying ... tendon and assisting in the relief of ... with high density foam padding molds itself ...
... The RCAI Bariatric Knee Immobilizer is ... lateral stays with a breathable foam material ... , ,The posterior aspect of the ... custom anatomical fit. The loop and lock ...
Medicine Products: